Compare CGEM & GAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGEM | GAU |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.7M | 670.3M |
| IPO Year | 2021 | N/A |
| Metric | CGEM | GAU |
|---|---|---|
| Price | $11.84 | $3.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $28.13 | $3.00 |
| AVG Volume (30 Days) | 707.4K | ★ 2.9M |
| Earning Date | 02-26-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $352,642,000.00 |
| Revenue This Year | N/A | $82.50 |
| Revenue Next Year | N/A | $57.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 111.43 |
| 52 Week Low | $5.68 | $1.00 |
| 52 Week High | $13.33 | $3.26 |
| Indicator | CGEM | GAU |
|---|---|---|
| Relative Strength Index (RSI) | 57.77 | 67.39 |
| Support Level | $11.53 | $3.01 |
| Resistance Level | $12.99 | $3.26 |
| Average True Range (ATR) | 0.76 | 0.15 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 61.36 | 83.33 |
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.